Hims & Hers Health (NYSE:HIMS) Lowered to “Hold” Rating by Leerink Partners

Hims & Hers Health (NYSE:HIMS) was downgraded by analysts at Leerink Partners from a “strong-buy” rating to a “hold” rating in a research note issued on Tuesday,Zacks.com reports.

Several other equities research analysts have also commented on the stock. Wall Street Zen lowered shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Deutsche Bank Aktiengesellschaft set a $31.00 price target on shares of Hims & Hers Health and gave the stock a “hold” rating in a research report on Tuesday, February 10th. TD Cowen decreased their price target on shares of Hims & Hers Health from $20.00 to $17.00 and set a “hold” rating on the stock in a research note on Tuesday. Citigroup cut their price objective on Hims & Hers Health from $16.50 to $13.25 and set a “sell” rating for the company in a research note on Tuesday. Finally, Evercore set a $24.00 target price on Hims & Hers Health in a research report on Tuesday. Two analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and four have assigned a Sell rating to the stock. According to data from MarketBeat, Hims & Hers Health has a consensus rating of “Reduce” and an average target price of $32.27.

Hims & Hers Health Price Performance

Shares of Hims & Hers Health stock opened at $15.43 on Tuesday. The firm has a market cap of $3.51 billion, a PE ratio of 30.26, a P/E/G ratio of 2.90 and a beta of 2.43. Hims & Hers Health has a twelve month low of $13.74 and a twelve month high of $70.43. The company has a quick ratio of 1.64, a current ratio of 1.88 and a debt-to-equity ratio of 1.67. The business has a 50-day moving average price of $27.79 and a 200 day moving average price of $39.76.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, February 23rd. The company reported $0.08 EPS for the quarter, beating the consensus estimate of $0.02 by $0.06. The company had revenue of $617.82 million for the quarter, compared to analyst estimates of $619.48 million. Hims & Hers Health had a return on equity of 22.25% and a net margin of 5.47%.Hims & Hers Health’s quarterly revenue was up 28.4% compared to the same quarter last year. During the same period last year, the company earned $0.11 earnings per share. Sell-side analysts predict that Hims & Hers Health will post 0.29 earnings per share for the current fiscal year.

Hims & Hers Health announced that its board has approved a share buyback plan on Monday, November 17th that allows the company to repurchase $250.00 million in shares. This repurchase authorization allows the company to buy up to 3% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s management believes its shares are undervalued.

Insiders Place Their Bets

In other news, insider Deborah M. Autor sold 7,054 shares of the business’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total transaction of $258,952.34. Following the transaction, the insider directly owned 6,175 shares in the company, valued at $226,684.25. The trade was a 53.32% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Michael Chi sold 13,750 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total value of $504,762.50. Following the transaction, the chief operating officer owned 305,161 shares in the company, valued at approximately $11,202,460.31. The trade was a 4.31% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 82,963 shares of company stock worth $2,944,621. 17.71% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Hims & Hers Health

A number of hedge funds have recently modified their holdings of the company. Farallon Capital Management LLC raised its stake in Hims & Hers Health by 30.8% during the third quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock worth $609,561,000 after purchasing an additional 2,533,271 shares during the period. Invesco Ltd. raised its position in shares of Hims & Hers Health by 502.2% during the 2nd quarter. Invesco Ltd. now owns 2,552,405 shares of the company’s stock valued at $127,237,000 after buying an additional 2,128,587 shares during the period. Norges Bank acquired a new position in Hims & Hers Health in the fourth quarter valued at approximately $62,153,000. Clear Street LLC purchased a new position in Hims & Hers Health in the second quarter worth approximately $83,582,000. Finally, Clear Street Group Inc. purchased a new position in Hims & Hers Health in the third quarter worth approximately $87,372,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Trending Headlines about Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Beat on EPS and subscriber growth — HIMS reported Q4 revenue up ~28% YoY and an EPS beat while saying subscribers have crossed 2.5 million, showing demand resilience. Hims & Hers Health Reports Mixed Q4 Earnings, Subscribers Cross 2.5 Million
• Positive Sentiment: Acquisition and 2026 revenue guidance provide upside potential — Management projects 2026 revenue of $2.7–$2.9B (above some estimates) and highlighted the Eucalyptus acquisition as an incremental revenue driver. Hims & Hers forecasts 2026 revenue above estimates
• Positive Sentiment: Bullish analyst/features note long‑term growth path — Bullish writeups highlight multi‑year international expansion, Eucalyptus’ contribution and a path to much larger revenue/EBITDA over time. Hims & Hers Health: Don’t Get Lost In The Weeds
• Neutral Sentiment: Unusual options activity — Heavy call buying was reported, which can indicate speculative bullish interest but is not definitive on fundamentals.
• Negative Sentiment: Soft near‑term guidance and margin pressure — Q1 revenue guidance came in below street estimates and margins showed contraction, prompting investor concern about short‑term growth and profitability. Hims & Hers Stock Slips Despite Q4 Earnings Beat, Margins Contract
• Negative Sentiment: Regulatory and SEC scrutiny — The company disclosed an SEC probe and management addressed scrutiny over compounding of GLP‑1 products, raising legal and operational risk for its core weight‑loss business. Hims & Hers Health discloses SEC investigation over copycat GLP-1s; stock falls
• Negative Sentiment: Analyst downgrades and price‑target cuts — Several firms trimmed forecasts and ratings (Citigroup cut its target to $13.25 with a sell), increasing near‑term sell pressure. Analyst price target and rating actions

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.